Various forms of arthritis afflict nearly 600 million people worldwide and add $16.5 billion to the United States’ healthcare bill, yet there are few engineered cartilage tissue therapies available to sufferers. In Nature Reviews Rheumatology, University of California, Irvine biomedical engineers shared insights into the effective treatment of severe osteoarthritis and rheumatoid arthritis and the clinical trial and regulatory efforts that are going to be necessary to bring products to market.
